论文部分内容阅读
应用重组促红细胞生成素(r-HuEPO)治疗60例慢性肾功能衰竭(CRF)患者的贫血,根据红细胞压积(Hct)水平,将病人分为25U/kg组、50U/kg组、100U/kg组及200U/kg组,共4组。治疗8周后患者的Hct及血红蛋白(Hb)均有升高,依赖输血者不需再输血。血清铁蛋白(FePr)随Hct、Hb的上升而下降,呈负相关趋势。未透析病人的血浆粘度在治疗后明显上升(P<0.01)。血白细胞(WBC)、血小板(Pc)、血钙(Ca)、血磷(P)、血尿素氮(BUN)、肌酐(Cr)、叶酸(FA)及B_(12)等水平治疗前后无明显差别。治疗后症状明显减轻或消失。结果认为r-HuEPO能有效地纠正CRF的贫血,安全可靠、副作用少。治疗中应随时监测铁储备,必要时应及时补充铁剂。
The patients were divided into 25 U / kg group, 50 U / kg group and 100 U / kg group according to the level of hematocrit (Hct) in 60 patients with chronic renal failure (CRF) treated with recombinant human erythropoietin kg group and 200U / kg group, a total of 4 groups. Patients after 8 weeks of treatment of Hct and hemoglobin (Hb) have increased, dependent on blood transfusion were no longer need blood transfusion. Serum ferritin (FePr) decreased with the rise of Hct and Hb, showing a negative correlation trend. The plasma viscosity of non-dialysis patients increased significantly after treatment (P <0.01). No significant changes were found in the levels of WBC, Pc, Ca, P, BUN, Cr, FA and B 12 before and after treatment difference. Symptoms after treatment significantly reduced or disappeared. The results showed that r-HuEPO can effectively correct the anemia of CRF, safe and reliable, less side effects. Iron treatment should be monitored at any time, when necessary, iron supplements should be promptly.